Overall, Kamdar said for patients with relapsed large B-cell lymphoma who have failed two or more lines of treatments, she would choose CAR T-cell treatment first and then bispecific antibodies.

Approval of new CAR-T may have ‘immediate impact’ on treatment of large B-cell lymphoma . ByDrew Amorosi. Add topic to email alerts Receive an email when new articles are posted on .

The FDA has approved Novartis' chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma ...

WU-CART-007 is currently being evaluated in a global Phase 1/2 clinical trial for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma ...

Clinical study results of CART Lymphoma Therapy CTL019 showed positive results thus, giving hope to. Patients with specific types of lymphomas may be helped by a new treatment option from Novartis.

Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.

Among patients with relapsed or refractory large B cell lymphoma (LBCL), lisocabtagene maraleucel may improve outcomes compared with standard of care (SOC) therapy in the second line, according to ...

Treatment with lisocabtagene maraleucel, also known as liso-cel, demonstrated clinical activity and appeared tolerable among patients with relapsed/refractory mantle cell lymphoma (MCL), according to ...

At one-year follow-up, phase 2 clinical trial results showed that most patients with relapsed or treatment resistant mantle cell lymphoma responded to chimeric antigen receptor (CAR)-T cell therapy.

Thu, 03 Apr 2025 21:11:01 GMT (1743714661969) Story Infinite Scroll - News3 v1.0.0 (common) 0634509e3d4a6767ae344aff0e8d87e8c38db281 ...

Novartis is testing CTL019, its investigational chimeric antigen receptor T cell therapy, or CART, on 15 adult patients with the most-common non-Hodgkins lymphoma, called diffuse large B-cell ...